A Study to Evaluate the Pharmacokinetics (PK), Efficacy and Safety and Tolerability of Pegcetacoplan in Patients With TA-TMA After Hematopoietic Stem Cell Transplantation (HSCT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05148299|
Recruitment Status : Recruiting
First Posted : December 8, 2021
Last Update Posted : May 1, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Transplant-Associated Thrombotic Microangiopathy||Drug: Pegcetacoplan||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||12 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||open label, single arm, multicenter|
|Masking:||None (Open Label)|
|Official Title:||An Open-label, Single-arm, Multicenter Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Pegcetacoplan in Patients With Transplant-associated Thrombotic Microangiopathy (TA-TMA) After Hematopoietic Stem Cell Transplantation (HSCT)|
|Actual Study Start Date :||February 1, 2022|
|Estimated Primary Completion Date :||March 31, 2024|
|Estimated Study Completion Date :||March 31, 2024|
20-cc glass vials-1080 mg
- Pegcetacoplan PK parameter AUC0-tau [ Time Frame: Week 24 ]Area under the concentration-time curve over the dosing interval
- Pegcetacoplan PK parameter Cmax [ Time Frame: Week 24 ]Maximum observed serum concentration
- Pegcetacoplan PK parameter Tmax [ Time Frame: Week 24 ]Time of maximum measured serum concentration
- Pegcetacoplan PK parameter Ctrough [ Time Frame: Week 24 ]Observed serum concentration predose
- Absolute levels, change from baseline, and percent change in sC5b-9 [ Time Frame: Week 24 ]Absolute levels, change from baseline, and percent change from baseline to Week 24 in biomarker of complement activation sC5b-9
- Number of participants reaching clinical response at week 24 [ Time Frame: Week 24 ]A participant will be declared as reaching a clinical response upon improvement in laboratory markers of TMA and resolution of TMA clinical symptoms
- Number of participants reaching TMA response at week 24 [ Time Frame: Week 24 ]A participant will be declared as reaching TMA response upon improvement in laboratory markers of TMA
- Overall survival [ Time Frame: Day 100 from diagnosis ]Survival
- Overall survival [ Time Frame: Week 24 from treatment start ]Survival
- Time to clinical response. [ Time Frame: From treatment start to first documentation of attainment of a clinical response ]Both clinical response sustained at week 24 and clinical response at any time during the study will be assessed.
- Time to TMA response. [ Time Frame: From treatment start to first documentation of attainment of a TMA response ]Both TMA response sustained at week 24 and TMA response at any time during the study will be assessed.
- Duration of clinical response. [ Time Frame: From the first observed clinical response until the response criteria is no longer fulfilled or until end of study ]
- Duration of TMA response. [ Time Frame: From the first observed TMA response until the response criteria is no longer fulfilled or until end of study ]
- TA-TMA relapse at Week 24. [ Time Frame: Week 24 ]A participant will be declared as relapsing upon appearance of laboratory markers of TMA
- Number of participants reaching clinical response at week 12 [ Time Frame: Week 12 ]
- Number of participants reaching TMA response at week 12 [ Time Frame: Week 12 ]
- Number of participants with treatment-related adverse events. [ Time Frame: From treatment start to end of study, an average of 6 months ]Occurrence and severity of treatment-emergent adverse events.
- Number of participants with clinically significant changes in vital signs. [ Time Frame: Week 24 ]Occurrence of clinically significant changes in vital signs.
- Number of participants with clinically significant changes in abnormal electrocardiogram findings. [ Time Frame: Week 24 ]Occurrence of clinically significant abnormal electrocardiogram findings.
- Number of participants with antibodies to polyethylene glycol (PEG) and pegcetacoplan throughout treatment and follow-up periods. [ Time Frame: from treatment start to the end of the study, an average of 6 months. ]Presence of antibodies to polyethylene glycol (PEG) and pegcetacoplan throughout treatment and follow-up periods.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Male and female patients aged ≥ 18 years at the time of informed consent form (ICF) signature.
- Received allogeneic HSCT.
- Diagnosis of TA-TMA established, as per laboratory markers indicating TMA.
- Have a diagnosis of TA-TMA that persists despite initial management of any triggering condition.
- Have rUPCR ≥ 1 mg/mg.
Women of childbearing potential, defined as any women who have experienced menarche and who are NOT permanently sterile or postmenopausal, must have a negative serum pregnancy test at screening and agree to use protocol-defined methods of contraception for the duration of the study and 8 weeks after their last IMP dose.
Note: Postmenopausal is defined as having had 12 consecutive months with no menses without an alternative medical cause.
Men must agree to the following for the duration of the study and 8 weeks after their last dose of IMP:
- Avoid fathering a child.
- Use protocol-defined methods of contraception.
- Refrain from donating sperm.
- Patient and/or legally authorized representative must be capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF.
- Positive direct Coombs test.
- Known familial or acquired ADAMTS13 deficiency.
- Known Shiga toxin-related hemolytic uremic syndrome.
- Known bone marrow or graft failure.
- Diagnosis of disseminated intravascular coagulation.
- Diagnosis of veno-occlusive disease (VOD).
- Active GI bleeding (hematemesis or hematochezia) at baseline.
- Body weight < 30 kg and > 100 kg.
- Uncontrolled systemic bacterial or fungal infection, presence or suspicion of sepsis.
- Previously or currently treated with a complement inhibitor (approved or investigational).
- Pregnancy or breastfeeding.
- Positive human immunodeficiency virus antibody at screening or documented in pre-HSCT medical record.
- Hepatitis C virus detectable by polymerase chain reaction at screening or documented in pre-HSCT medical record.
- Chronic inactive hepatitis B virus with viral loads > 1000 IU/mL (> 5000 copies/mL) at screening or documented in pre-HSCT medical record. Eligible patients who are chronic active carriers (≤ 1000 IU/mL) must receive prophylactic antiviral treatment (e.g., entecavir, tenofovir, lamivudine) according to local country guidelines.
- Known or suspected hereditary fructose intolerance.
- Hypersensitivity to pegcetacoplan or any of its excipients.
- Inability to cooperate with study procedures or any condition that, in the opinion of the investigator, could increase the patient's risk by participating in the study or confound the outcome of the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05148299
|Contact: Luis Lopez Lazaro, MD||0041 79 834 17 78||Luis.LopezLazaro@sobi.com|
|United States, California|
|Ryotaro Nakamura, MD||Recruiting|
|Duarte, California, United States, 91010|
|United States, Minnesota|
|Hassan AlKhateeb, MD||Recruiting|
|Rochester, Minnesota, United States, 55905|
|Michael Loschi, MD||Recruiting|
|Nice, France, 06202|
|Flore Sicre de Fontbrune, MD||Recruiting|
|Paris, France, 75010|
|Jerome Cornillon, MD||Recruiting|
|Saint-Priest-en-Jarez, France, 42270|
|Panagiotis Tsirigotis, MD||Recruiting|
|Athens, Chaidari, Greece, 12462|
|Ioannis Baltadakis, MD||Recruiting|
|Athens, Greece, 10676|
|Ioanna Sakellari, MD||Recruiting|
|Thessaloníki, Greece, 57010|
|Antonio Risitano, MD||Recruiting|
|Avellino, Italy, 83100|
|Giovanni Grillo, MD||Not yet recruiting|
|Milan, Italy, 20162|
|Elisabetta Terruzi, MD||Recruiting|
|Monza, Italy, 20900|
|Luca Castagna, MD||Recruiting|
|Palermo, Italy, 900146|
|Simona Sica, MD||Recruiting|
|Roma, Italy, 00168|
|Rafael Francisco Duarte Palomino, MD||Recruiting|
|Madrid, Spain, 28222|
|Responsible Party:||Swedish Orphan Biovitrum|
|Other Study ID Numbers:||
|First Posted:||December 8, 2021 Key Record Dates|
|Last Update Posted:||May 1, 2023|
|Last Verified:||April 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Blood Platelet Disorders